prnewswire.com - 14 Oct 2026 15:48
NASDAQ | TSX: ACB Revised Hostile Bid continues to significantly undervalue Aurora; fails ...
NASDAQ : ACB
Aurora Cannabis Inc. (ACB)Healthcare : Drug Manufacturers - Specialty & Generic$3,96
-0.03 (-0.75%) today
Aurora Cannabis Inc. is a leading company in the global cannabis industry, focusing on the cultivation, production, and sale of various cannabis and cannabis-derived products across Canada and internationally. Beyond its core product offerings, the company engages in a broad spectrum of related activities, including the design and engineering of facilities, cannabis breeding programs, research and development, and both wholesale and retail distribution channels. For medical users, Aurora provides a diverse selection of products such as different strains of dried cannabis, cannabis oils, capsules, and topical kits. Their inventory also includes ancillary items like vaporizers, vaporizer accessories, herb mills (specifically for CanniMed products), grinders, and secure containers for vaporizers. The company is actively involved in developing advanced medical cannabis products, with ongoing work on oral, topical, edible, and inhalable formulations. Furthermore, Aurora manages CanvasRX, a network of centers dedicated to cannabis counseling and community outreach. Its service portfolio extends to providing patient support, specialized design and construction services, and comprehensive analytical testing for cannabis products. Aurora Cannabis Inc. manages an extensive collection of brands, including Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. The company's main corporate office is located in Edmonton, Canada.
Open
$4,00
High
$4,09
Low
$3,96
Mkt. cap
250.71M
Avg. vol.
1.33M
Volume
598.78K
52-wk high
$6,36
52-wk low
$2,56
Shares outstanding
63.31M
prnewswire.com - 14 Oct 2026 15:48
NASDAQ | TSX: ACB Revised Hostile Bid continues to significantly undervalue Aurora; fails ...
fool.com - 12 Oct 2026 16:45
Curaleaf recently raised its offer for Aurora Cannabis to $5. Aurora is reviewing the bid ...
defenseworld.net - 12 Oct 2026 01:59
BeOne Medicines (NASDAQ: ONC - Get Free Report) and Aurora Cannabis (NASDAQ: ACB - Get Fre...
247wallst.com - 08 Oct 2026 10:09
A Q1 FY2027 revenue record from Tilray Brands (NASDAQ:TLRY) is drawing heavy selling, beca...
prnewswire.com - 08 Oct 2026 07:05
NASDAQ | TSX: ACB Multi-million-dollar investment results in increased domestic production...
prnewswire.com - 06 Oct 2026 16:30
Aurora's Special Committee will commence a thorough and independent review of the revised ...
marketbeat.com - 06 Oct 2026 11:56
The multi-year cannabis sector bear market is starting to give way to a calculated wave of...
prnewswire.com - 05 Oct 2026 18:11
NASDAQ | TSX: ACB Curaleaf has yet to file a Notice of Variation and Change to revise its ...
defenseworld.net - 05 Oct 2026 13:41
Shares of Aurora Cannabis Inc. (TSE: ACB - Get Free Report) rose 15.6% on Monday. The stoc...
defenseworld.net - 05 Oct 2026 11:01
Aurora Cannabis Inc. (NASDAQ: ACB - Get Free Report) was the recipient of some unusual opt...
Latest reported earnings
Q2 2026
Report date: Aug 5, 2026
EPS / Est.
$-0.046 / $-0.13
+64.60% beat
Revenue / Est.
$47.56M / $47.45M
+0.23% beat
Past earnings
| Fiscal period | Report date | EPS / Est. | Revenue / Est. |
|---|---|---|---|
| Q1 2026 | Jun 11, 2026 | $-0.71 / $-0.07 (-914.14% miss) | $60.98M / $54.42M (+12.05% beat) |
| Q4 2025 | Feb 4, 2026 | $0.023 / $0.097 (-75.95% miss) | $68.59M / $67.26M (+1.97% beat) |
| Q3 2025 | Nov 5, 2025 | $-0.652 / $0.03 (-2274.83% miss) | $64.88M / $62.05M (+4.57% beat) |
| Q2 2025 | Aug 6, 2025 | $-0.19 / $0.18 (-205.56% miss) | $72.00M / $70.76M (+1.75% beat) |
| Q1 2025 | Jun 18, 2025 | $-0.243 / $0.11 (-321.08% miss) | $62.91M / $61.72M (+1.93% beat) |
| Q4 2024 | Feb 5, 2025 | $0.396 / $0.003 (+11688.69% beat) | $61.29M / $55.50M (+10.43% beat) |
| Q3 2024 | Nov 6, 2024 | $0.04 / $-0.22 (+118.18% beat) | $59.95M / $51.56M (+16.29% beat) |
| Q2 2024 | Aug 7, 2024 | $-0.11 / $-0.35 (+68.57% beat) | $60.97M / $56.67M (+7.57% beat) |
| Q1 2024 | Jun 20, 2024 | $-0.191 / $-0.18 (-6.37% miss) | $49.76M / $51.34M (-3.07% miss) |
| Q4 2023 | Feb 8, 2024 | $-0.389 / $-0.1 (-288.99% miss) | $48.60M / $47.82M (+1.63% beat) |
| Q3 2023 | Nov 9, 2023 | $-0.5 / $-0.04 (-1150.00% miss) | $46.67M / $46.44M (+0.50% beat) |
| Q2 2023 | Aug 10, 2023 | $-0.604 / $-0.392 (-53.85% miss) | $56.66M / $56.86M (-0.36% miss) |
Miguel Martin - CEO
Kevin Niland - Senior Director of Strategic Finance - Global FP&A and Investor Relations
Alex Miller - Executive Vice President of Operations & Supply Chain
David Aird - Executive Vice President of Information Technology
Kerry Miller - Managing Director for Australia & New Zealand
Miguel Martin - Chief Executive Officer & Executive Chairman
Rick Savone - Senior Vice President of Global Government Relations
Michelle Lefler - Vice President of Communications & Public Relations
Nathalie Clark - Executive Vice President, General Counsel & Corporate Secretary
Simona King - Chief Financial Officer
Lori Schick - Executive Vice President of Human Resources